Multiple Myeloma Mentorship Summits
Hematology-Oncology
Curriculum:
Multiple Myeloma Mentorship Program
Multiple Myeloma Mentorship Program
Credits:
2.5 ANCC Contact Hours
2.5 ANCC Contact Hours
Launch Date:
September 16, 2014
September 16, 2014
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Advanced Practice Registered Nurses, inpatient/outpatient oncology nurses, nurse practitioners in community/secondary/tertiary cancer centers, oncology/hematology nurse educators, other healthcare professionals
Relevant Terms:
Deep Vein Thrombosis, Immunomodulatory Drugs, Multiple Myeloma, Peripheral Neuropathy, Proteasome Inhibitors, Skeletal-Related Events
Beth Faiman, PhDc, MSN, APN-BC, AOCN®
Beth Faiman, PhDc, MSN, APN-BC, AOCN®
Cleveland Clinic Taussig Cancer Institute
Bio
Beth Faiman is currently an Adult Nurse Practitioner in the Department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio. She is also a full-time pre-doctoral research fellow and PhD candidate at the Frances Payne Bolton School of Nursing at Case Western Reserve in Cleveland, Ohio pursuing a PhD in nursing research. She is adjunct faculty at Ursuline College, Case Western Reserve University, and Kent State University. She received the 2012 Excellence in Medical Oncology and 2013 Commendation for Patient and Nursing Education Awards sponsored by The Oncology Nursing Society. Ms. Faiman received a bachelor of science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio, completed in 1996. She received a master of science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio in 2002. She holds an advanced oncology nurse certification through ONCC.
Ms. Faiman is an active author, presenter, and educator on the topic of multiple myeloma, plasma cell dyscrasias, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. She is an appointed delegate on the International Myeloma Foundation Nurse Leadership Board. She is currently Editor-in-Chief of The Oncology Nurse APN/PA. She has authored several book chapters relating to diagnosis and management of multiple myeloma and blood disorders, and has written numerous articles relating to the diagnosis and treatment of myeloma, palliation, and cancer symptom management.
Sandra E. Kurtin, MS, RN, ANP-C, AOCN®
Sandra E. Kurtin, MS, RN, ANP-C, AOCN®
The University of Arizona Cancer Center
Bio
Sandra E. Kurtin is a Nurse Practitioner, Clinical Assistant Professor of Medicine, and Adjunct Clinical Assistant Professor of nursing at The University of Arizona Cancer Center in Tucson, AZ. She has 29 years of oncology nursing experience, 23 of those in advanced practice, 18 as a Nurse Practitioner in oncology. She maintains a busy clinical practice in an NCI-designated Comprehensive Cancer Center with expertise in hematological malignancies, GI malignancies, clinical trials, and symptom management.
Ms. Kurtin received her Master of Science in Nursing from the University of Arizona. She is widely published in peer-reviewed journals, lectures nationally and internationally, and maintains active membership in local, regional, national, and international professional and patient advocacy oncology organizations.
Ms. Kurtin received her Master of Science in Nursing from the University of Arizona. She is widely published in peer-reviewed journals, lectures nationally and internationally, and maintains active membership in local, regional, national, and international professional and patient advocacy oncology organizations.
| 1. | Identify the epidemiology of multiple myeloma, including disparities that exist across various ethnic groups | 2. | Explain the pathophysiology of multiple myeloma |
| 3. | Describe the diagnostic workup of patients with multiple myeloma, including interpretation of common laboratory tests | 4. | Describe the various methods of staging patients with multiple myeloma |
| 5. | Identify patient- and disease-related characteristics that influence selection of appropriate treatment for MM | 6. | Compare the safety, efficacy, and mechanisms of action of common agents used in the first-line, induction, maintenance, and relapsed/refractory settings |
| 7. | Apply emerging evidence to inform the role and timing of stem cell transplantation | 8. | Describe advances in maintenance and relapsed/refractory therapy that can potentially prolong survival and improve quality of life in patients with MM |
| 9. | Utilize education strategies to help patients understand their disease and treatment options | 10. | Implement an evidence-based nursing care plan for patients with multiple myeloma based upon disease- and treatment-related symptoms, and assist with patient compliance and treatment adherence |
| 11. | Evaluate new findings about the impact of bisphosphonates on skeletal-related events and survival in patients with MM | 12. | Implement nursing strategies to prevent and manage deep venous thrombosis in patients with multiple myeloma |
| 13. | Help patients cope with long-term survivorship issues | 14. | Utilize education strategies to help patients recognize and manage side effects |
| 1. | Identify the epidemiology of multiple myeloma, including disparities that exist across various ethnic groups |
| 2. | Explain the pathophysiology of multiple myeloma |
| 3. | Describe the diagnostic workup of patients with multiple myeloma, including interpretation of common laboratory tests |
| 4. | Describe the various methods of staging patients with multiple myeloma |
| 5. | Identify patient- and disease-related characteristics that influence selection of appropriate treatment for MM |
| 6. | Compare the safety, efficacy, and mechanisms of action of common agents used in the first-line, induction, maintenance, and relapsed/refractory settings |
| 7. | Apply emerging evidence to inform the role and timing of stem cell transplantation |
| 8. | Describe advances in maintenance and relapsed/refractory therapy that can potentially prolong survival and improve quality of life in patients with MM |
| 9. | Utilize education strategies to help patients understand their disease and treatment options |
| 10. | Implement an evidence-based nursing care plan for patients with multiple myeloma based upon disease- and treatment-related symptoms, and assist with patient compliance and treatment adherence |
| 11. | Evaluate new findings about the impact of bisphosphonates on skeletal-related events and survival in patients with MM |
| 12. | Implement nursing strategies to prevent and manage deep venous thrombosis in patients with multiple myeloma |
| 13. | Help patients cope with long-term survivorship issues |
| 14. | Utilize education strategies to help patients recognize and manage side effects |
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
ACCREDITATION STATEMENT
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CREDIT DESIGNATION
Summit I
Summit I
This educational activity for 1.5 contact hour(s) is provided by Postgraduate Institute for Medicine.
Approved for 0.4 Advanced Practice Nurse Pharmacology Credits.
California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.5 contact hours.
Summit II
This educational activity for 1.0 contact hour(s) is provided by Postgraduate Institute for Medicine.
Approved for 0.3 Advanced Practice Nurse Pharmacology Credits.
California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hours.
California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hours.
HOW TO CLAIM CREDIT
Credits will be awarded automatically upon passing each activity post-test with a grade of 70% or better and completion of each activity evaluation.
AMERICANS WITH DISABILITIES ACT
In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Beth Faiman, PhDc, MSN, APN-BC, AOCN®, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc.; Speakers' Bureau, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc.
Sandra E. Kurtin, MS, RN, ANP-C, AOCN®, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc.; Speakers' Bureau, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS, Jocelyn Timko, BS, Diedrea White, BA, and Deborah Middleton, MS hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Beth Faiman, PhDc, MSN, APN-BC, AOCN®, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc.; Speakers' Bureau, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc.
Sandra E. Kurtin, MS, RN, ANP-C, AOCN®, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc.; Speakers' Bureau, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS, Jocelyn Timko, BS, Diedrea White, BA, and Deborah Middleton, MS hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
- Fair balance
- Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
- No single product or service is overrepresented when other equal competing products or services are available for inclusion
- Scientific objectivity of studies mentioned in the materials or used as the basis for content
- Appropriateness of patient care recommendations made to learners
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.5 hours
FEE STATEMENT
There is no fee for this educational activity.
CONTACT INFORMATION
To contact PIM, please visit www.pimed.com.
Jointly provided by:
This activity is supported by an educational grant from Millennium: The Takeda Oncology Company.
